ITP: a new regulatory issue!
Semple
John W
JW
The Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada. semplej@smh.toronto.on.ca
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000954:Antigens, Surface / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D015551:Autoimmunity / Q000187:drug effects; D003713:Dendritic Cells / Q000276:immunology / Q000473:pathology; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D012157:Mononuclear Phagocyte System / Q000276:immunology / Q000473:pathology; D010587:Phagocytosis / Q000276:immunology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D013154:Spleen / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000954:Antigens, Surface; D001323:Autoantibodies; D003907:Dexamethasone